FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2735565585> ?p ?o ?g. }

• W2735565585 endingPage "682" @default.
• W2735565585 startingPage "666" @default.
• W2735565585 abstract "Background Evidence on the long-term clinical benefits of individual members of angiotensin II receptor blockers is limited given the lack of head-to-head studies. We conducted a network meta-analysis to determine the comparative efficacy of different members within this drug class with respect to outcomes of (i) blood pressure reduction (at 24 and 52 weeks) and (ii) prevention of cardiovascular disease (>104 weeks). Methods A systematic literature review was conducted – Protocol registration: (PROSPERO – CRD42014007067) – to identify relevant literature from the following databases: Cochrane Library, PubMed, Medline and EMBASE; searched from inception to July 2016. Randomised controlled trials (RCTs) were included if they reported long-term effectiveness relating to blood pressure, mortality, myocardial infarction or stroke. Eligible studies included those with placebo or specific active-treatment comparators (either another angiotensin II receptor blockers or hydrochlorothiazide). A Bayesian random-effects network model was used to combine direct within-trial comparisons between treatment groups with indirect evidence from other trials. Results Thirty-six studies were identified, representing 28 unique trials. Blood pressure reduction, based on 12 studies (n = 807) with fixed dosing regimen, was found to be similar amongst members of the angiotensin receptor blocker drug class at both 24 and 52 weeks. A network meta-analysis of five studies (n = 16,716) with a treat-to-target approach found that prevention of all-cause mortality, stroke and myocardial infarction was similar across the angiotensin-receptor blockers therapies initiated. Conclusions Current evidence is insufficient to show differences in any members within the angiotensin II receptor blocker drug class with respect to blood pressuring lowering effects or a reduction in cardiovascular diseases. Evidence on the long-term clinical benefits of individual members of angiotensin II receptor blockers is limited given the lack of head-to-head studies. We conducted a network meta-analysis to determine the comparative efficacy of different members within this drug class with respect to outcomes of (i) blood pressure reduction (at 24 and 52 weeks) and (ii) prevention of cardiovascular disease (>104 weeks). A systematic literature review was conducted – Protocol registration: (PROSPERO – CRD42014007067) – to identify relevant literature from the following databases: Cochrane Library, PubMed, Medline and EMBASE; searched from inception to July 2016. Randomised controlled trials (RCTs) were included if they reported long-term effectiveness relating to blood pressure, mortality, myocardial infarction or stroke. Eligible studies included those with placebo or specific active-treatment comparators (either another angiotensin II receptor blockers or hydrochlorothiazide). A Bayesian random-effects network model was used to combine direct within-trial comparisons between treatment groups with indirect evidence from other trials. Thirty-six studies were identified, representing 28 unique trials. Blood pressure reduction, based on 12 studies (n = 807) with fixed dosing regimen, was found to be similar amongst members of the angiotensin receptor blocker drug class at both 24 and 52 weeks. A network meta-analysis of five studies (n = 16,716) with a treat-to-target approach found that prevention of all-cause mortality, stroke and myocardial infarction was similar across the angiotensin-receptor blockers therapies initiated. Current evidence is insufficient to show differences in any members within the angiotensin II receptor blocker drug class with respect to blood pressuring lowering effects or a reduction in cardiovascular diseases." @default.
• W2735565585 created "2017-07-21" @default.
• W2735565585 creator A5022995296 @default.
• W2735565585 creator A5029465719 @default.
• W2735565585 creator A5032453977 @default.
• W2735565585 creator A5050865817 @default.
• W2735565585 creator A5073926476 @default.
• W2735565585 creator A5082899051 @default.
• W2735565585 creator A5083713721 @default.
• W2735565585 creator A5090142411 @default.
• W2735565585 date "2018-06-01" @default.
• W2735565585 modified "2023-10-18" @default.
• W2735565585 title "Comparative Efficacy of Angiotensin II Antagonists in Essential Hypertension: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials" @default.
• W2735565585 cites W1481238878 @default.
• W2735565585 cites W1556581720 @default.
• W2735565585 cites W1976734710 @default.
• W2735565585 cites W1978977357 @default.
• W2735565585 cites W1979030376 @default.
• W2735565585 cites W1981060913 @default.
• W2735565585 cites W1981940583 @default.
• W2735565585 cites W1987395490 @default.
• W2735565585 cites W1989118729 @default.
• W2735565585 cites W1989318421 @default.
• W2735565585 cites W1995861586 @default.
• W2735565585 cites W1997355903 @default.
• W2735565585 cites W2004760663 @default.
• W2735565585 cites W2011581788 @default.
• W2735565585 cites W2013354239 @default.
• W2735565585 cites W2021334280 @default.
• W2735565585 cites W2021584319 @default.
• W2735565585 cites W2022729051 @default.
• W2735565585 cites W2023314157 @default.
• W2735565585 cites W2031335602 @default.
• W2735565585 cites W2031971366 @default.
• W2735565585 cites W2037877892 @default.
• W2735565585 cites W2040557955 @default.
• W2735565585 cites W2041240420 @default.
• W2735565585 cites W2044257849 @default.
• W2735565585 cites W2044773944 @default.
• W2735565585 cites W2047867745 @default.
• W2735565585 cites W2048902899 @default.
• W2735565585 cites W2048927121 @default.
• W2735565585 cites W2050360890 @default.
• W2735565585 cites W2054479029 @default.
• W2735565585 cites W2054796764 @default.
• W2735565585 cites W2056976690 @default.
• W2735565585 cites W2057707360 @default.
• W2735565585 cites W2061528318 @default.
• W2735565585 cites W2064868021 @default.
• W2735565585 cites W2066291670 @default.
• W2735565585 cites W2066759120 @default.
• W2735565585 cites W2067083151 @default.
• W2735565585 cites W2073735186 @default.
• W2735565585 cites W2074147400 @default.
• W2735565585 cites W2074633080 @default.
• W2735565585 cites W2075675369 @default.
• W2735565585 cites W2075759443 @default.
• W2735565585 cites W2080463077 @default.
• W2735565585 cites W2080742733 @default.
• W2735565585 cites W2086614658 @default.
• W2735565585 cites W2101849950 @default.
• W2735565585 cites W2105875912 @default.
• W2735565585 cites W2108595845 @default.
• W2735565585 cites W2112846582 @default.
• W2735565585 cites W2118286022 @default.
• W2735565585 cites W2120879945 @default.
• W2735565585 cites W2123917216 @default.
• W2735565585 cites W2126120464 @default.
• W2735565585 cites W2126125759 @default.
• W2735565585 cites W2133416234 @default.
• W2735565585 cites W2133861409 @default.
• W2735565585 cites W2146732398 @default.
• W2735565585 cites W2150529573 @default.
• W2735565585 cites W2159729565 @default.
• W2735565585 cites W2160452209 @default.
• W2735565585 cites W2162271484 @default.
• W2735565585 cites W2162304120 @default.
• W2735565585 cites W2167732511 @default.
• W2735565585 cites W2190019669 @default.
• W2735565585 cites W3021250193 @default.
• W2735565585 cites W3022903699 @default.
• W2735565585 cites W4234841815 @default.
• W2735565585 doi "https://doi.org/10.1016/j.hlc.2017.06.721" @default.
• W2735565585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28807582" @default.
• W2735565585 hasPublicationYear "2018" @default.
• W2735565585 type Work @default.
• W2735565585 sameAs 2735565585 @default.
• W2735565585 citedByCount "13" @default.
• W2735565585 countsByYear W27355655852018 @default.
• W2735565585 countsByYear W27355655852020 @default.
• W2735565585 countsByYear W27355655852021 @default.
• W2735565585 countsByYear W27355655852022 @default.
• W2735565585 countsByYear W27355655852023 @default.
• W2735565585 crossrefType "journal-article" @default.
• W2735565585 hasAuthorship W2735565585A5022995296 @default.
• W2735565585 hasAuthorship W2735565585A5029465719 @default.
• W2735565585 hasAuthorship W2735565585A5032453977 @default.
• W2735565585 hasAuthorship W2735565585A5050865817 @default.

• next